MedTrace Logo

Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects

NCT07584304 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-05-13

No results posted yet for this study

Summary

An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

YHP2508C

Test drug

DRUG

YHR2603

Comparator drug

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • GIMPO WOORI HOSPITAL · 11, Gamam-ro, Gimpo-si, Gyeonggi-do, Republic of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-10
Primary Completion
2026-09-15
Completion
2026-09-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07584304 on ClinicalTrials.gov